TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20352259

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy + irrigation of gallbladder bed with 20 mL 0.5% bupivacaine solution
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy + irrigation of gallbladder bed with bupivacaine + 10 mL 0.5% bupivacaine solution every 6 h
Number of subjects: 30

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 30
Study: 17606880

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide 500 mg once daily for 4 days combined with oral prednisone 60 mg once daily for 5 days (n = 16)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide and prednisone (treatment group)
Number of subjects: 35
Study: 15658142

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 30

Group type: COMPARATOR
Intervention: Plain radiographs
Number of subjects: 30
Study: 11881887

Group type: EXPERIMENTAL
Intervention: Gp CVP (central venous pressure guided fluid challenges)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gp DOP (oesophageal Doppler ultrasonography guided fluid challenges)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gp CVP
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gp DOP
Number of subjects: 90

Group type: COMPARATOR
Intervention: Gp CON
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 90
Study: 10458232

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy with ifosfamide/etoposide on days 1-3 and cyclophosphamide/doxorubicin on day 5, followed by granulocyte colony-stimulating factor; maintenance included four alternating cycles of ifosfamide/etoposide and doxorubicin/CTX.
Number of subjects: 53

Group type: COMPARATOR
Intervention: CTX dose levels during maintenance (two arms).
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overall treatment regimen including dose-intensification.
Number of subjects: 53
Study: 7563558

Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy with minimal counseling
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 44-mg transdermal nicotine therapy with minimal counseling
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy with individual counseling
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 44-mg transdermal nicotine therapy with individual counseling
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy with group counseling
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 44-mg transdermal nicotine therapy with group counseling
Number of subjects: 504

Group type: COMPARATOR
Intervention: Minimal contact treatment
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 44-mg transdermal nicotine therapy
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: 22-mg transdermal nicotine therapy
Number of subjects: 504
Study: 2348582

Group type: EXPERIMENTAL
Intervention: Reperfusion group (ICT or PTCA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-reperfusion group
Number of subjects: 16
Study: 115801

Group type: EXPERIMENTAL
Intervention: Intranasal self‐administration of an aqueous solution of a glutaraldehyde‐treated timothy grass pollen allergen
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30540715

Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (IV TXA) 2g (1g before incision and 1g before wound closure)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (PO TXA) 1.95g 2 hours preoperatively
Number of subjects: 83

Group type: COMPARATOR
Intervention: Comparison of IV TXA and PO TXA
Number of subjects: 83
Study: 30218546

Group type: EXPERIMENTAL
Intervention: EM fungal OTUs at colder sites
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: EM fungal richness at colder sites
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: EM fungal OTUs composition
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: EM fungal OTUs restricted to low mean annual temperatures
Number of subjects: 75
Study: 27236888

Group type: EXPERIMENTAL
Intervention: Xinfeng Capsule (XFC), 0.5 g each pill, three pills each time, 3 times per day for 3 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sulfasalazine (SASP), 0.25 g per tablet, 4 tablets each time, twice per day for 3 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: Comparison between XFC and SASP
Number of subjects: 59
Study: 25256187

Group type: EXPERIMENTAL
Intervention: BDD-NET (therapist-supported, Internet-based cognitive-behavioral therapy) for 12 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Secondary outcome measures (depression, global functioning, quality of life)
Number of subjects: 23
Study: 22493419

Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg loading dose followed by 2 mg weekly)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Lapatinib (1,500 mg orally daily)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Trastuzumab and lapatinib (1,000 mg orally daily)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Chemotherapy alone (control group not explicitly defined)
Number of subjects: 121
Study: 20138357

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery (APCam01)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Closed-loop delivery after rapidly absorbed meals (APCam02)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery (APCam03)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Closed-loop delivery (pooled data)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Closed-loop delivery
Number of subjects: 19
Study: 17179256

Group type: EXPERIMENTAL
Intervention: Landiolol at 0.1 mg/kg infused 4 min before intubation in normotensive patients
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Landiolol at 0.2 mg/kg in hypertensive patients
Number of subjects: 88

Group type: COMPARATOR
Intervention: Fentanyl at 2 μg/kg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Landiolol (any dose)
Number of subjects: 88
Study: 15908277

Group type: EXPERIMENTAL
Intervention: Home-based walking and resistance exercise program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study: 12488239

Group type: EXPERIMENTAL
Intervention: buspirone (10 mg twice daily)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: paroxetine (20 mg daily)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: venlafaxine-XR (75 mg daily)
Number of subjects: 51

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 51
Study: 10629348

Group type: EXPERIMENTAL
Intervention: Streptokinase plus aspirin
Number of subjects: 313

Group type: COMPARATOR
Intervention: Streptokinase alone
Number of subjects: 313
Study: 9121851

Group type: EXPERIMENTAL
Intervention: 2-hourly CPT
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 4-hourly CPT
Number of subjects: 63

Group type: COMPARATOR
Intervention: No CPT
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 63
Study: 1292072

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg capsule three times daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (multiple-vitamin tablet three times daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 3966421

Group type: COMPARATOR
Intervention: 0 mg PN X HCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5 mg PN X HCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 10.0 mg PN X HCl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20.0 mg PN X HCl
Number of subjects: 0
Study: 30710185

Group type: EXPERIMENTAL
Intervention: Rapha® system application by the participant and a health professional at home
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Rapha® system applied by the participant at home
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard protocol used in Brazil performed by a health professional at the hospital
Number of subjects: 15
Study: 27926661

Group type: EXPERIMENTAL
Intervention: Low-dose prostacyclin infusion (1.0 ng/kg/min)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (saline infusion)
Number of subjects: 0
Study: 24373022

Group type: EXPERIMENTAL
Intervention: Paramedian inserted mini-implants
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (median mini-implants of the same size)
Number of subjects: 21
Study: 26054362

Group type: EXPERIMENTAL
Intervention: Short Self-Regulation Questionnaire (SSRQ)
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: Self-Regulation Questionnaire (SRQ)
Number of subjects: 834
Study: 23286722

Group type: EXPERIMENTAL
Intervention: 20 minutes sun exposure
Number of subjects: 6

Group type: COMPARATOR
Intervention: 40 minutes sun exposure
Number of subjects: 6
Study: 19286168

Group type: EXPERIMENTAL
Intervention: Tailored Group Triple P - Positive Parenting Program
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 75
Study: 17084676

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS) therapy
Number of subjects: 138
Study: 15076779

Group type: EXPERIMENTAL
Intervention: Anesthesia (lidocaine injected into the anterior talofibular and calcaneofibular ligament, 1.5 cc each)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (no anesthesia)
Number of subjects: 14
Study: 11818693

Group type: EXPERIMENTAL
Intervention: Interferon-alpha alone or in combination with ribavirin
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (18 non-IDUs)
Number of subjects: 27
Study: 9803049

Group type: EXPERIMENTAL
Intervention: Prolonged transdermal fentanyl (FENtd)
Number of subjects: 48
Study: 8087191

Group type: EXPERIMENTAL
Intervention: Aluminium-adsorbed pertussis vaccine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-adsorbed pertussis vaccine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Two-component vaccine as primary immunization
Number of subjects: 49

Group type: COMPARATOR
Intervention: Monocomponent vaccine as primary immunization
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Total serum IgE levels
Number of subjects: 49
Study: 2676440

Group type: EXPERIMENTAL
Intervention: Ketanserin (20-40 mg twice a day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 855889

Group type: COMPARATOR
Intervention: Patient information package insert (FDA version)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Patient information brochure (study's version)
Number of subjects: 253
Study: 31181179

Group type: EXPERIMENTAL
Intervention: DT‐BCTQ (Decision Tree Boston Carpal Tunnel Questionnaire)
Number of subjects: 4470

Group type: EXPERIMENTAL
Intervention: DT‐BCTQ
Number of subjects: 4470
Study: 27765695

Group type: EXPERIMENTAL
Intervention: 1,000 IU daily
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 50,000 IU weekly
Number of subjects: 21
Study: 26437499

Group type: EXPERIMENTAL
Intervention: Essential Oil (EO) mouthrinse
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 0.075% Cetylpyridinium Chloride (CPC) mouthrinse
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control (5% hydroalcohol solution)
Number of subjects: 165
Study: 24971679

Group type: EXPERIMENTAL
Intervention: IVGTT after 55 min of cycle‐ergometer exercise at 60% VO2peak
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: OGTT after 55 min of cycle‐ergometer exercise at 60% VO2peak
Number of subjects: 10
Study: 23151156

Group type: EXPERIMENTAL
Intervention: Acupuncture plus usual care
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: Counseling plus usual care
Number of subjects: 755

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 755

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 755
Study: 19701600

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC) performed between 24 and 72 hours after endoscopic retrograde cholangiopancreaticography (ERCP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC) performed more than 72 hours after endoscopic retrograde cholangiopancreaticography (ERCP)
Number of subjects: 0
Study: 17543413

Group type: EXPERIMENTAL
Intervention: 30 mg pioglitazone once daily for 6 months
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo once daily for 6 months
Number of subjects: 60
Study: 15146932

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide 5‐mononitrate (5‐ISMN) tablet
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide 5‐mononitrate intravenous infusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide dinitrate (ISDN) intravenous infusion
Number of subjects: 18
Study: 11219479

Group type: EXPERIMENTAL
Intervention: Fluvastatin ER 80 mg QPM
Number of subjects: 695

Group type: COMPARATOR
Intervention: Fluvastatin IR 40 mg QPM
Number of subjects: 695

Group type: COMPARATOR
Intervention: Fluvastatin IR 40 mg BID
Number of subjects: 695
Study: 9475657

Group type: EXPERIMENTAL
Intervention: Three 10‐min walks per day (short bouts)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: One 30‐min walk per day (long bouts)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No training (control)
Number of subjects: 47
Study: 9160550

Group type: EXPERIMENTAL
Intervention: Sustained release (SR) adinazolam
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 2739019

Group type: EXPERIMENTAL
Intervention: Antilipid A antibody
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 38
Study: 474664

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Animal supplements
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vegetable supplements
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: In vitro addition of zinc
Number of subjects: 100
Study: 31099405

Group type: EXPERIMENTAL
Intervention: GnRHa
Number of subjects: 60
Study: 28723837

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5% with epinephrine 5 μg/mL
Number of subjects: 57
Study: 26297360

Group type: EXPERIMENTAL
Intervention: Remote ischaemic conditioning (RIC)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Sham-RIC (control)
Number of subjects: 220
Study: 23782459

Group type: EXPERIMENTAL
Intervention: Tadalafil 5 mg once daily
Number of subjects: 1026

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1026
Study: 21324150

Group type: COMPARATOR
Intervention: Standard of care lifestyle intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behaviourally‐based, matched prescriptive physical activity and diet change program
Number of subjects: 0
Study: 19164399

Group type: EXPERIMENTAL
Intervention: Pneumatic compression (group I, n=24)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Low-level laser (group II, n=23)
Number of subjects: 47
Study: 17947832

Group type: EXPERIMENTAL
Intervention: Corticosteroid (1 drop of 0.1% dexamethasone disodium phosphate)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 55
Study: 15059069

Group type: EXPERIMENTAL
Intervention: Amphotericin B lipid complex (ABLC) at 1 mg/kg/d
Number of subjects: 105

Group type: COMPARATOR
Intervention: Conventional amphotericin B (c‐AmB) at 0.6 mg/kg/d
Number of subjects: 105
Study: 11120550

Group type: EXPERIMENTAL
Intervention: Wellstart‐SLC course training for hospital staff
Number of subjects: 970

Group type: COMPARATOR
Intervention: Control group (hospitals not exposed to the Wellstart‐SLC course)
Number of subjects: 970
Study: 9056026

Group type: EXPERIMENTAL
Intervention: Visual localization task with varying tilt angles (0, 45, 90, 135, 180, 225, 270, 315 degrees)
Number of subjects: 9
Study: 8410889

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 79

Group type: COMPARATOR
Intervention: Tracheal intubation
Number of subjects: 79
Study: 2421751

Group type: EXPERIMENTAL
Intervention: xamoterol 0.025 mg kg‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study: 1151357

Group type: EXPERIMENTAL
Intervention: Marijuana
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31211469

Group type: EXPERIMENTAL
Intervention: Typing pattern monitored remotely during a 6-month follow-up while dopaminergic medications were being titrated.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Novel algorithm based on recursive neural networks for detecting responses to medication.
Number of subjects: 61

Group type: COMPARATOR
Intervention: Dopaminergic treatment titration.
Number of subjects: 61
Study: 30084893

Group type: COMPARATOR
Intervention: Telephone-administered interpersonal psychotherapy (tele-IPT)
Number of subjects: 0
Study: 26784645

Group type: EXPERIMENTAL
Intervention: Sling
Number of subjects: 147

Group type: COMPARATOR
Intervention: Control
Number of subjects: 147
Study: 24625273

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subacromial corticosteroid injection and a physiotherapist-led exercise programme
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subacromial corticosteroid injection and an advice and exercise leaflet
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Blind subacromial corticosteroid injection and a physiotherapist-led exercise programme
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Blind subacromial corticosteroid injection and an advice and exercise leaflet
Number of subjects: 252

Group type: COMPARATOR
Intervention: Comparison between injection interventions
Number of subjects: 252

Group type: COMPARATOR
Intervention: Comparison between exercise interventions
Number of subjects: 252

Group type: COMPARATOR
Intervention: Long-term outcomes
Number of subjects: 252
Study: 23484573

Group type: EXPERIMENTAL
Intervention: Nintendo Wii
Number of subjects: 42

Group type: COMPARATOR
Intervention: PlayStation2
Number of subjects: 42
Study: 20434602

Group type: EXPERIMENTAL
Intervention: EST+SWC
Number of subjects: 34

Group type: COMPARATOR
Intervention: SWC
Number of subjects: 34
Study: 17923401

Group type: EXPERIMENTAL
Intervention: Fish-oil supplementation (FO-S)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15741836

Group type: EXPERIMENTAL
Intervention: Pizotifen (1.5 mg)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 11893261

Group type: EXPERIMENTAL
Intervention: Ultrasonography (USG)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Palpation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CT or USG
Number of subjects: 25
Study: 10213009

Group type: EXPERIMENTAL
Intervention: irinotecan (CPT-11) at a dose of 350 mg/m2 every 3 weeks
Number of subjects: 279

Group type: EXPERIMENTAL
Intervention: irinotecan (CPT-11)
Number of subjects: 279
Study: 7537967

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low molecular weight (LMW) heparin
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Heparinoid (danaparoid sodium; Org 10172)
Number of subjects: 11
Study: 2170885

Group type: EXPERIMENTAL
Intervention: Estrogen/progestin therapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: Untreated estrogen-deficient girls
Number of subjects: 35

Group type: COMPARATOR
Intervention: History of radiation therapy
Number of subjects: 35
Study: 696759

Group type: EXPERIMENTAL
Intervention: Visual-spatial training condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 31365280

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 256

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 256
Study: 27658337

Group type: EXPERIMENTAL
Intervention: Straw phonation exercises for 3 minutes
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Straw phonation exercises for 5 minutes
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (complete voice rest)
Number of subjects: 27
Study: 25785441

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg) + Zinc (30 mg/d) + Selenium (150 μg/d)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (no zinc and selenium supplementation)
Number of subjects: 76
Study: 24015990

Group type: EXPERIMENTAL
Intervention: Intravenous iron (200 mg iron sucrose, three daily infusions starting within 24 hours of admission)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard hospital care (control group)
Number of subjects: 80
Study: 21412833

Group type: EXPERIMENTAL
Intervention: LEV 500 mg/day
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: LEV 1,000 mg/day
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19477914

Group type: EXPERIMENTAL
Intervention: Abstainers (n = 25)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Controls (n = 38)
Number of subjects: 104
Study: 17184625

Group type: EXPERIMENTAL
Intervention: Self-management of oral anticoagulation
Number of subjects: 930

Group type: COMPARATOR
Intervention: Conventional measurement by the general practitioner
Number of subjects: 930
Study: 14749240

Group type: EXPERIMENTAL
Intervention: Flaxseed (25 g ground flaxseed muffin)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Soy (25 g soy flour muffin)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 11545629

Group type: EXPERIMENTAL
Intervention: Topical ofloxacin (0.3% ophthalmic solution every 30 minutes for 4 hours before surgery)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin (0.3% ophthalmic solution every 30 minutes for 4 hours before surgery)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined topical and oral ofloxacin (one 400-mg tablet administered 24-26, 12-14, and 2 hours before surgery)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined topical and oral ciprofloxacin (four 100-mg tablets administered 24-26, 12-14, and 2 hours before surgery)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined topical and oral therapy with ofloxacin
Number of subjects: 34

Group type: COMPARATOR
Intervention: Topical therapy alone (ofloxacin)
Number of subjects: 34